THYROCARE2024-07-012024-09-30 THYROCARE2024-07-012024-09-30 THYROCARE2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member THYROCARE2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member THYROCARE2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539871 THYROCARE NOTLISTED Thyrocare Technologies Limited Equity 2024-04-01 2025-03-31 2024-10-23 2024-10-16 INR Crores Half yearly 15:00:00 16:05:00 2024-10-23 2024-10-23 true Cash Flow Indirect Not applicable Single segment Diagnostic Testing Services 2024-07-01 2024-09-30 Unaudited Standalone 1630500000.00 21210000.00 1651710000.00 469350000.00 12850000.00 -4130000.00 276890000.00 6340000.00 99360000.00 387690000.00 1248350000.00 403360000.00 0.00 403360000.00 123100000.00 -15590000.00 107510000.00 0.00 295850000.00 0.00 0.00 0.00 0.00 295850000.00 -500000.00 295350000.00 0.00 0.00 529530000.00 10 5.59 5.58 0.00 0.00 5.59 5.58 0.00 0.02 0.65 Notes : 1 The above standalone unaudited financial results of the Company were reviewed and recommended by the Audit Committee on 23 October 2024 and subsequently approved by the Board of Directors at its meeting held on 23 October 2024. The statutory auditors of the Company have expressed an unmodified conclusion on the unaudited standalone financial results for the quarter and six months ended September 30, 2024. 2 These unaudited standalone financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable. 3 The Company has assessed the recoverable amount of the investment made in its wholly owned subsidiary Nueclear Healthcare Limited (‘NHL’) as value in use, being the higher of Fair Value less Cost of Disposal and Value in Use. For the six months ended September 30, 2024, NHL has reported earning before interest tax and deprecation of Rs. 0.72 Crores and has generated cash inflow from operating activities amounting to Rs. 2.54 Crores. NHL still has accumulated losses carried forward from the previous years, hence the Company continues to assess the profitability and growth of NHL. The management does not foresee any further requirement of impairment of its investment made in NHL as at September 30, 2024 other than those already provided for in the books of account amounting to Rs. 44.33 Crores (31 March 2024: INR 44.33 Crores). 4 The Company has completed the acquisition of the diagnostic and pathological services business of Polo as a going concern (on a slump sale basis) on July 29, 2024 (“Closing date”) in terms of the Business Transfer Agreement (“BTA”) entered on July 2, 2024, with Polo Labs Private Limited and has commenced the relevant operations on a going-concern basis w.e.f. July 29, 2024. The Company had paid consideration of Rs.4.26 Crores and has accounted for the said acquisition as per Ind AS 103- ‘Business Combinations’ in the Standalone financial statements and has recognized goodwill amounting to Rs.1.22 Crores post-acquisition of net assets. 5 Subsequent to the quarter end, the Company has executed Business Transfer Agreement (“BTA”) with Vimta Labs Limited (“Vimta”) for acquiring Vimta’s diagnostic and pathological services business as a going concern (on a slump sale basis), subject to fulfilment of the Conditions Precedent (“CP”) as set out in the BTA, on October 11, 2024. The amount of consideration involved is Rs.7.00 Crores and other requisite working capital adjustments. 6 The Unaudited standalone financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). 7 During the quarter ended 30 September 2024, the Company has forfeited 2,142 equity stock options granted to employees under employees stock option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable. 8 In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Company. 9 Previous periods'/years' figures have been regrouped/ reclassified wherever required, to make them comparable with the figure for the current period/year. Single segment 2024-04-01 2024-09-30 Unaudited Standalone 3066800000.00 52920000.00 3119720000.00 890400000.00 13400000.00 3360000.00 542620000.00 15600000.00 193900000.00 705600000.00 2364880000.00 754840000.00 0.00 754840000.00 223200000.00 -15800000.00 207400000.00 0.00 547440000.00 0.00 0.00 0.00 0.00 547440000.00 -4800000.00 542640000.00 0.00 0.00 529530000.00 10 10.34 10.32 0.00 0.00 10.34 10.32 0.00 0.04 0.49 other expenses 387690000.00 other expenses 705600000.00 1183340000.00 6070000.00 9770000.00 12210000.00 308580000.00 0.00 0.00 0.00 1797060000.00 0.00 0.00 58830000.00 1855890000.00 259100000.00 71160000.00 3706120000.00 430660000.00 561780000.00 439850000.00 431600000.00 82680000.00 0.00 22070000.00 1537980000.00 0.00 134940000.00 2103580000.00 0.00 0.00 5809700000.00 529530000.00 4261990000.00 4791520000.00 4791520000.00 0.00 0.00 154570000.00 154570000.00 35230000.00 189800000.00 0.00 395550000.00 250750000.00 646300000.00 93030000.00 36720000.00 52330000.00 0.00 828380000.00 1018180000.00 5809700000.00 15770000.00 26300000.00 -43060000.00 0.00 -58440000.00 0.00 0.00 0.00 0.00 36030000.00 0.00 53240000.00 0.00 193950000.00 0.00 5200000.00 0.00 9330000.00 0.00 -39440000.00 0.00 4340000.00 63640000.00 0.00 0.00 0.00 0.00 -20000.00 0.00 258160000.00 1013000000.00 0.00 0.00 0.00 125540000.00 0.00 887460000.00 0.00 35000000.00 0.00 0.00 0.00 35040000.00 0.00 0.00 0.00 78490000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 853030000.00 0.00 0.00 0.00 0.00 0.00 0.00 4340000.00 0.00 0.00 0.00 708840000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 197600000.00 0.00 33780000.00 953150000.00 15800000.00 0.00 0.00 -1200330000.00 395970000.00 0.00 395970000.00 35590000.00 431560000.00 -700000.00 -6400000.00 0.00 0.00 -200000.00 -1600000.00